Amgen Inc. (AMGN) Bundle
An Overview of Amgen Inc. (AMGN)
General Summary of Amgen Inc. (AMGN)
Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. The company specializes in biotechnology and develops innovative human therapeutics.
Key Products and Services:
- Enbrel (autoimmune disease treatment)
- Prolia (osteoporosis medication)
- Neulasta (cancer supportive care)
- LUMAKRAS (cancer therapy)
Total Revenue for 2023: $27.6 billion
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $27.6 billion |
| Net Income | $8.2 billion |
| Research & Development Expenses | $4.8 billion |
Industry Leadership
Market Position: Ranked #1 in biotechnology by market capitalization
Global Presence: Operations in over 100 countries
Number of Employees: 24,000 worldwide
Stock Performance: NASDAQ: AMGN, Trading at approximately $285 per share as of January 2024
Mission Statement of Amgen Inc. (AMGN)
Mission Statement of Amgen Inc. (AMGN) in 2024
Amgen's mission statement focuses on serving patients by transforming scientific discoveries into innovative medicines that address serious illnesses.
Core Mission Components
Scientific Innovation
Amgen invested $4.6 billion in research and development in 2023. Key research areas include:
- Oncology
- Cardiovascular disease
- Neuroscience
- Inflammation
Patient-Centric Approach
| Metric | 2024 Data |
|---|---|
| Patients Served Globally | 10.2 million |
| Therapeutic Areas Covered | 8 major disease categories |
| Medicines in Global Market | 27 approved therapies |
Operational Performance
Amgen's 2023 financial performance:
- Total Revenue: $27.8 billion
- Net Income: $8.3 billion
- Global Employees: 24,000
Strategic Research Focus
| Research Area | Investment |
|---|---|
| Biotechnology | $2.1 billion |
| Precision Medicine | $1.5 billion |
| Gene Therapy | $980 million |
Vision Statement of Amgen Inc. (AMGN)
Vision Statement of Amgen Inc. (AMGN)
Pioneering Innovative Biotechnology SolutionsAmgen's vision focuses on transforming innovative science and biotechnology into therapies that significantly improve patients' lives globally.
Key Vision Components
Global Healthcare ImpactAmgen targets serving approximately 4 million patients worldwide with its innovative biotechnology treatments as of 2024.
| Geographic Reach | Patient Coverage | Treatment Areas |
|---|---|---|
| 100+ Countries | 4 Million Patients | Oncology, Cardiovascular, Inflammation |
Amgen invests $4.6 billion annually in research and development to drive breakthrough medical innovations.
- R&D Investment: $4.6 Billion
- Active Research Programs: 25+ Therapeutic Areas
- Patent Portfolio: 8,500+ Active Patents
Commitment to developing cost-effective and accessible biotechnology solutions for complex medical conditions.
| Medication Accessibility | Cost Reduction Strategy | Patient Support Programs |
|---|---|---|
| 50% Reduced Cost Treatments | $500 Million Patient Assistance Budget | 12 Active Support Programs |
Advanced biotechnology platforms driving medical breakthroughs in precision medicine.
- AI-Driven Research Platforms: 7
- Machine Learning Models: 15
- Genomic Research Initiatives: 22
Core Values of Amgen Inc. (AMGN)
Core Values of Amgen Inc. (AMGN) in 2024
Scientific Innovation and Research Excellence
R&D investment in 2023: $4.6 billion
| Research Focus Areas | Investment Percentage |
|---|---|
| Oncology | 38% |
| Cardiovascular Diseases | 22% |
| Inflammation | 18% |
Patient-Centered Approach
Patient support programs in 2023:
- Patient assistance programs covering 87% of medication costs
- Direct patient support budget: $127 million
- Global patient access programs in 45 countries
Ethical Business Practices
Compliance metrics for 2023:
| Compliance Measure | Performance |
|---|---|
| Ethical Conduct Training Completion | 99.8% |
| Supplier Code of Conduct Adherence | 96% |
Sustainability and Environmental Responsibility
Environmental sustainability achievements in 2023:
- Carbon emission reduction: 42% from 2015 baseline
- Renewable energy usage: 65% of total energy consumption
- Water conservation: 35% reduction in water usage
Diversity, Equity, and Inclusion
Workforce diversity statistics for 2023:
| Diversity Metric | Percentage |
|---|---|
| Women in Leadership Positions | 48% |
| Racial/Ethnic Minorities in Workforce | 41% |
Amgen Inc. (AMGN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.